High rate of complete response achieved with ligelizumab in patients with moderate to severe chronic spontaneous urticaria throughout the phase 2b core study

被引：0
|
作者：
Bernstein, Jonathan A. [1 ,2 ]
Maurer, Marcus [3 ]
Gimenez-Arnau, Ana [4 ]
Soong, Weily [5 ]
Sitz, Karl [6 ]
Hua, Eva [7 ]
Barbier, Nathalie [8 ]
Barve, Avantika [9 ]
Severin, Thomas [8 ]
Janocha, Reinhold [8 ]
机构：
[1] Univ Cincinnati, Coll Med, Cincinnati, OH USA
[2] Bernstein Clin Res Ctr, Cincinnati, OH USA
[3] Charite Univ Med Berlin, Dept Dermatol & Allergy, Berlin, Germany
[4] Univ Autonoma Barcelona, Dept Dermatol, Hosp Mar Parc Salut Mar, Barcelona, Spain
[5] Clin Res Ctr Alabama, Alabama Allergy & Asthma Ctr, Birmingham, AL USA
[6] Little Rock Allergy & Asthma Clin, Clin Res Ctr, Little Rock, AR USA
[7] Shanghai Novartis Trading Ltd, Shanghai, Peoples R China
[8] Novartis Pharma AG, Basel, Switzerland
[9] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27362
引用
收藏
页码：AB137 / AB137
页数：1
相关论文
共 50 条
  • [21] Ligelizumab as add-on therapy for patients with H1-antihistamine-refractory chronic spontaneous urticaria: primary results of a placebo- and active-controlled phase 2b dose-finding study
    Maurer, M.
    Gimenez-Arnau, A.
    Sussman, G.
    Loeffler, J.
    Barve, A.
    Severin, T.
    Janocha, R.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 121 - 121
  • [22] Remibrutinib Improves Chronic Spontaneous Urticaria in Patients Irrespective of Previous Anti-IgE Treatment: Results From a Phase 2b Study
    Greiner, Alexander
    Guduri, Sridhar
    Leflein, Jeffrey
    Haemmerle, Sibylle
    Lheritier, Karine
    Walsh, Pauline
    Nikolaev, Ivan
    Gimenez-Arnau, Ana
    Maurer, Marcus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB131 - AB131
  • [23] Systemic inflammatory response and calcification markers in patients with long lasting moderate-severe chronic spontaneous urticaria
    Grzanka, Alicja
    Machura, Edyta
    Misiolek, Maciej
    Polaniak, Renata
    Kasperski, Jacek
    Kasperska-Zajac, Alicja
    EUROPEAN JOURNAL OF DERMATOLOGY, 2015, 25 (01) : 26 - 28
  • [24] Systemic inflammatory response and calcification markers in patients with long lasting moderate-severe chronic spontaneous urticaria
    Alicja Grzanka
    Edyta Machura
    Maciej Misiolek
    Renata Polaniak
    Jacek Kasperski
    Alicja Kasperska-Zajac
    European Journal of Dermatology, 2015, 25 : 26 - 28
  • [25] Remibrutinib (LOU064) reduces the use of rescue medication in patients with chronic spontaneous urticaria: Findings from a Phase 2b study
    Maurer, M.
    Reed, J.
    Staubach-renz, P.
    Lheritier, K.
    Walsh, P.
    Meti, V.
    Nikolaev, I.
    Haemmerle, S.
    Gimenez-Arnau, A. M.
    ALLERGY, 2023, 78 : 14 - 14
  • [26] Remibrutinib (LOU064) treatment improves hive severity in patients with chronic spontaneous urticaria: Findings from a Phase 2b study
    Gimenez-Arnau, A. M.
    Hayama, K.
    Jain, V.
    Sitz, K.
    Lheritier, K.
    Nikolaev, I.
    Walsh, P.
    Haemmerle, S.
    Maurer, M.
    ALLERGY, 2023, 78 : 245 - 245
  • [27] Remibrutinib Treatment Did Not Impact Total Serum Immunoglobulin Levels or Infection Rates in Patients With Chronic Spontaneous Urticaria: Phase 2b Study Results
    Carr, Warner
    Gimanez-Armau, Ana
    Lheritler, Karine
    Haemmerle, Sibylle
    Zharkov, Artem
    Dahale, Swapnil
    Hayama, Koremasa
    Snyder, Robert
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB8 - AB8
  • [28] Comparably high Exposure to chronic spontaneous Urticaria in Patients with moderate and severe Disease Activity: Results from the ASSURE-csU Study
    Marsland, Alexander
    Abuzakouk, Mohamed
    Balp, Maria Magdalena
    Berard, Frederic
    Canonica, Giorgio Walter
    Gimenez-Arnau, Ana
    Grattan, Clive
    Hollis, Kelly
    Hunter, Shannon
    Khalil, Sam
    Knulst, Andre C.
    Lacour, Jean-Phillipe
    Lynde, Charles
    McBride, Doreen
    Nakonechna, Alla
    Ortiz De Frutoz, Francisco J.
    Elberink, J. N. G. Oude
    Sussman, Gordon
    Weller, Karsten
    Maurer, Marcus
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 9 - 10
  • [29] A phase 2b trial of baricitinib, an oral JAK inhibitor, in patients with moderate to severe psoriasis
    Menter, Alan
    Disch, Damon
    Clemens, Jeffrey
    Janes, Jonathan
    Papp, Kim
    Macias, William
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB162 - AB162
  • [30] Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus
    Silverberg, Jonathan, I
    Pinter, Andreas
    Pulka, Grazyna
    Poulin, Yves
    Bouaziz, Jean-David
    Wollenberg, Andreas
    Murrell, Dedee F.
    Alexis, Andrew
    Lindsey, Lisa
    Ahmad, Faiz
    Piketty, Christophe
    Clucas, Alan
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (01) : 173 - 182
12345